BMS-817378

A comments to BMS-777607 suggest that this structure is the backup:

WO/2009/094427

BMS-777607

BMS homegrown Ph1 c-Met / AXL / Ron Inhibitor.  As of now PDB 3F82 has not yet been released.

The N-Oxide is a major metabolite, and from the trial notes its either toxic, potent, or prevalent… The J Med Chem doesn’t mention it.

More Her

‘nother ErbB 1,2,4 crystal forms app from BMS in US20070191375:

…

PDB Update

2GU8, AKT, Chiron, BMCL, 06, 4163

2OJ9, IGF-1R, BMS, BMCL, 07, 2317

‘Nother “Novel” VEGF candidate

BMS-582664 / Brivanib alaninate

WO/2007/038648 is a development ‘crystalline forms’ application from BMS.

Discovery: WO/2004/009784. Process: WO/2006/130657. It’s a prodrug / isostere rip on AZD-2171 / Cediranib / Recentin; WO/2000/047212

Sprycel ®

Sprycel ®, dasatinib, BMS-354825

Discovery: Bristol-Myers Squibb WO/2000/062778
US Approval: June 2006

wiki; PDB: 2GQG; FDA; J Med Chem ’06 6819;

Named after its inventor?

Takeda to BMS: pwned

So if your on the Aurora program at BMS you had to be a little disturbed when you saw US2006084650 with a priority date of: Oct 15, ’04 come out back in April ’06 as your earliest provisionals are from July 1 ’05. Who knows maybe there’s enough room in the sandbox for both. Takeda’s primary series appears to be the imidazopyrimidine anyways, but the pyrollo compounds are claimed and exemplified.

US20070004734; US20070004731

WO2006135796

‘Crystaline Forms’ of these HER1, 2, & 4 inhibitors. Interesting compounds. There’s already a BMCL on the series, and a Can J Chem on the route,

but this is the first I’ve heard of the morpholine.

Exelixis: bag of cash en route

While not saying what for I think its safe to assume they’ll hit a kinase or two along the way.

…upfront payment of $60 million in cash. Exelixis will also receive $20 million for each of up to three different drug candidates selected by Bristol-Myers Squibb at IND…

Sweetheart oncology deal. boring webcast here.

>> update: 8k,  The check must-a-been postdated.

BMS-354825 vs. VX-680

At least the PDB gave us something to look at a few days ago. Here’s a super-cool alignment of dasatinib in Abl to VX-680 in an abl mutant.